Stock Watch: J&J Puts On A Brave Face Ahead Of Stelara Biosimilars
Revenue Replacement Concerns Likely To Linger
Investors responded positively to the first third-quarter life sciences earnings report of the season although Stelara’s loss of exclusivity clouded the pitch.
